Vertex Pharmaceuticals (VRTX) EBITDA Margin Growth (3y) (2012 - 2026)

Vertex Pharmaceuticals (VRTX) EBITDA Margin Growth (3y) (2012 - 2026) Analysis & Trends

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) EBITDA Margin Growth (3y) (Qtr)
1 Vertex Pharmaceuticals 128.13 Bn 120.28 Bn 2.84 Bn -377.00
2 Regeneron Pharmaceuticals 112.33 Bn 104.33 Bn 3.93 Bn -204.00
3 Argenx Se 53.24 Bn 48.05 Bn 1.41 Bn 828,504.00
4 Revolution Medicines 43.64 Bn 43.64 Bn - -
5 BeOne Medicines 39.27 Bn 34.17 Bn 1.53 Bn 7,261.00
6 MindWalk Holdings 35.32 Bn 35.31 Bn 1.82 Bn -7.76 Bn
7 Royalty Pharma 33.72 Bn 35.84 Bn - -2,649.00
8 Alnylam Pharmaceuticals 30.58 Bn 27.27 Bn 992.69 Mn 9,003.00
9 Insmed 27.01 Bn 25.85 Bn 358.27 Mn 30,461.00
10 Roivant Sciences 26.16 Bn 26.85 Bn 1.16 Mn -2.41 Mn

Historic Data

Download Data
DateValue
Jun 30, 2026 -377.00
Mar 31, 2026 530.00
Dec 31, 2025 -708.00
Sep 30, 2025 -971.00
Jun 30, 2025 -1,155.00
Mar 31, 2025 -2,688.00
Dec 31, 2024 -711.00
Sep 30, 2024 -1,288.00
Jun 30, 2024 -13,074.00
Mar 31, 2024 -914.00
Dec 31, 2023 -655.00
Sep 30, 2023 -190.00
Jun 30, 2023 -593.00
Mar 31, 2023 -1,473.00
Dec 31, 2022 -30,907.00
Sep 30, 2022 3,781.00
Jun 30, 2022 2,169.00
Mar 31, 2022 1,738.00
Dec 31, 2021 2,767.00
Sep 30, 2021 2,693.00